Company intelligence / Profile preview

Suzhou Ribo Life Science Co., Ltd.

Kunshan, Jiangsu, Chinaribolia.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has six in-house discovered siRNA drugs in clinical trials, with four of them having advanced to Phase 2. Their lead programs include RBD4059 for Thromboembolism, RBD5044 and RBD7022 for Hyperlipidemia, RBD1016 for HBV, and RBD7007 and RBD2080 for Renal Diseases. In February 2025, they announced that their siRNA-based treatment for Autoimmune Diseases (RBD2080) received clinical approval in Australia.

Therapeutic areas: GastroenterologyCardiovascularMetabolic DisordersNephrologyImmunologyInfectious Diseases
Modalities: siRNAantisense oligonucleotides (ASO)aptamersoligonucleotide therapeutics
Industry: Biotech

Drug pipeline

10 assets

rbd7022

9 more assets in the full pipeline.

Partnerships

Boehringer Ingelheim (multi-target collaboration for NASH/MASH treatment, potential value exceeding $2 billion)Qilu Pharmaceutical (technology licensing agreement for PCSK9 phase-I asset)Pheiron (strategic collaboration for AI-assisted drug development of RNA therapeutics)

Beyond the preview

Go deeper on Suzhou Ribo Life Science Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Ribo Life Science Co., Ltd..